Asia
The cuts are being made as the company grapples with a debt of between $30 and $35B and a restructuring of its R&D in order to combat dramatically declining revenue from its generic pipeline.
Chinese interest in the J&J unit comes as the market for diabetes care in China is expected to grow rapidly.
An online comment can spur some serious discussion.
Innovent Biologics of Suzhou is planning a pre-IPO round and then an IPO for $200M in late 2018.
Suzhou Zelgen Biosciences completed a $62M series B financing to support its portfolio of small molecule and biologic drug candidates.
Here’s a look at the top six generic drug companies to work for.
The fine was over Teva paying bribes to foreign officials to win business in Russia, Ukraine and Mexico, the ministry said.
Hua Medicine of Shanghai expects to spend $200M over the next three years on its novel oral diabetes 2 treatment, dorzagliatin.
The Suzhou-based cancer-drug maker has been discussing a valuation of more than $1 billion.
Suzhou Kintor Pharma raised $44M in a funding led by Shenzhen Green Pine Capital Partners.
PRESS RELEASES